fimasartan and its Impurities
Fimasartan is an angiotensin receptor antagonist drug. It is employed in the treatment of both hypertension and heart failure. Reference standards of Fimasartan API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
 
	
			                                   
																				2-(2-Butyl-4-methyl-1-((2'-(1-methyl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide compound with 2-(2-butyl-4-methyl-1-((2'-(2-methyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide (1:1)
2-(2-Butyl-4-methyl-1-((2'-(1-methyl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide compound with 2-(2-butyl-4-methyl-1-((2'-(2-methyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide (1:1)
- Catalogue No.:PA 33 10510 
- CAS : - NA
- Molecular Formula : C56H66N14O2S2 
- Molecular Weight : 1031.35 
 
	
			                                   
																				2-(2-Butyl-4-methyl-6-oxo-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
2-(2-Butyl-4-methyl-6-oxo-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
- Catalogue No.:PA 33 10520 
- CAS : - 1361024-52-3
- Molecular Formula : C46H45N7OS 
- Molecular Weight : 743.97 
 
	
			                                   
																				2-(2-Butyl-4-methyl-6-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)methoxy)pyrimidin-5-yl)-N,N-dimethylacetamide
2-(2-Butyl-4-methyl-6-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-3-yl)methoxy)pyrimidin-5-yl)-N,N-dimethylacetamide
- Catalogue No.:PA 33 0101002 
- CAS : - NA
- Molecular Formula : C46H45N7O2 
- Molecular Weight : 727.91 

 
																				 
																				 
																				 
																				 
																				 
 
 
 
